Diagnosis and treatment of gastroesophageal reflux disease in Ohio Medicaid patients: practice patterns and temporal trends

被引:4
作者
Cooper, GS
Mourad, WA
Koroukian, SM
机构
[1] Univ Hosp Cleveland, Div Gastroenterol, Dept Med, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA
关键词
gastroesophageal reflux; proton pump inhibitors; histamine H2 antagonists; medicaid; gastrointestinal endoscopy;
D O I
10.1002/pds.818
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose There is a paucity of data about the use of procedures and prescription medications in the treatment of gastroesophageal reflux disease (GERD) in actual clinical practice. Methods Outpatient Ohio Medicaid claims from 1994 to 1998 were searched to identify patients with an initial diagnosis of GERD along with associated prescriptions and gastrointestinal procedures. Complications of GERD and comorbid illnesses were also determined. Results A total of 5579 patients were identified. Histamine-2 receptor antagonists (H2RA`s) were prescribed in 59%, followed by proton pump inhibitors (PPI's) (30%) and prokinetic drugs (17%). PPI's were more frequently prescribed to patients with GERD-related complications, peptic ulcer disease and major comorbidities, and patients who received PPI's were also more likely to undergo upper gastrointestinal endoscopy. The frequencies of upper endoscopy and barium studies were 20% and 11% respectively, with no change over the study period. There was an increased frequency of PPI therapy (17-43%) and decreased frequency of H2RA therapy (72-47%) from 1994 to 1998 which persisted after adjusting for potential differences in case mix. Conclusions In this population-based study, prescription of PPI's increased over time which likely reflected changes in clinician practice rather than patient mix. Despite a greater awareness of GERD complications, use of upper endoscopy did not increase. Although the cohort consists of predominantly low socioeconomic status, female patients, further studies should be conducted in other populations to confirm these findings. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 22 条
[1]  
[Anonymous], 1998, GASTROINTEST ENDOSC, V48, P663
[2]  
[Anonymous], PHARMACOEPIDEMIOLOGY
[3]  
Bashford JNR, 1998, BRIT MED J, V317, P452
[4]   RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[5]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[6]   The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage [J].
Cooper, GS ;
Chak, A ;
Lloyd, LE ;
Yurchick, PJ ;
Harper, DL ;
Rosenthal, GE .
GASTROINTESTINAL ENDOSCOPY, 2000, 51 (04) :423-426
[7]   The sensitivity of medicare claims data for case ascertainment of six common cancers [J].
Cooper, GS ;
Yuan, Z ;
Stange, KC ;
Dennis, LK ;
Amini, SB ;
Rimm, AA .
MEDICAL CARE, 1999, 37 (05) :436-444
[8]   Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment [J].
Cooper, GS ;
Yuan, Z ;
Stange, KC ;
Dennis, LK ;
Amini, SB ;
Rimm, AA .
MEDICAL CARE, 2000, 38 (04) :411-421
[9]  
Crawley J.A., 2000, J CLIN OUTCOMES MANA, V7, P29
[10]   An evidence-based appraisal of reflux disease management - the Genval workshop report [J].
Dent, J ;
Brun, J ;
Fendrick, AM ;
Fennerty, MB ;
Janssens, J ;
Kahrilas, PJ ;
Lauritsen, K ;
Reynolds, JC ;
Shaw, M ;
Talley, NJ .
GUT, 1999, 44 :S1-S16